Sustained in vitro interferon-beta release and in vivo toxicity of PLGA and PEG-PLGA nanoparticles

Abstract

Interferon-beta-1a (IFN-β-1a) can diminish the symptoms of relapsing-remitting multiple sclerosis.

Development of nanoparticle-delivery systems for antiviral agents: A review

“…This study reported that encapsulation increased the transport of the acyclovir through the multilayers of the corneal epithelial cells, which was related to the small size of the nanoparticles. In another study, Fodor-Kardos, Kiss et al [ 61 ] showed that interferon-beta-1a (IFN-β-1a) could be successfully incorporated into biopolymer-based nanoparticles fabricated from BSA and pegylated PLGA polymers. Cyclodextrins (CDs) are a family of cyclic oligosaccharides that have been also been used to encapsulate antivirals within their hydrophobic cores [ 141 ].…”

PLGA-Based Nanoparticles for Neuroprotective Drug Delivery in Neurodegenerative Diseases

“…Binding specific receptors exert its biological effect on the human cell surface to slow down MS progression [ 84 ]. To decrease drug dosage and improve its controlled release, Fodor-Kardos et al, designed IFN β-1a-loaded PEG-PLGA NPs by double emulsion solvent evaporation method with great encapsulation efficiency (95.9%) [ 85 ]. According to the used technic: 165 nm (PdI: 0.093) by DLS or 50–120 nm by SEM, differences in the NP size were observed by SEM, linked to the hydration of the sample.…”

“…: 0.7 to 2.5% E.E. : 95.9% In vitro: human blood plasma, primary hepatocytes from male Wistar rats In vivo: Wistar male rats N/A [ 85 ] LIF Double emulsion/solvent evaporation ø: 126 ± 50 nm In vitro: oligodendrocyte precursor cells from neonatal Sprague–Dawley rats Induce maturation of OPCs to myelin-competent oligodendrocytes within 3 days Promote high-quality myelin repair [ 88 ] Proteolipid Protein Double emulsion/solvent evaporation ø: 195.1 ± 10.1 nm PdI: 0.220 ζ potential: −20 mV D.L. : 20% E.E.…”

Neutrophil and Nanoparticles Delivery to Tumor: Is It Going to Carry That Weight?

“…[195][196][197] Currently, IFN therapy in patients with cancer, virus infections or autoimmune diseases is associated with severe side effects in a dose-dependent manner. [198,199] Several studies describe IFNs encapsulation into NPs to diminish drug toxicity, [200][201][202] but to the best of our knowledge, the suggested nanocarriers have never been regarded in the context of NΦ polarization. Future studies in this area have a potential to change the role of NΦ from an inert drug carrier to an active player in cancer therapy.…”